Literature DB >> 20861319

Intraventricular injection of myxoma virus results in transient expression of viral protein in mouse brain ependymal and subventricular cells.

Megan R France1, Diana L Thomas, Jia Liu, Grant McFadden, Amy L MacNeill, Edward J Roy.   

Abstract

Oncolytic viruses that selectively infect and lyse cancer cells have potential as therapeutic agents. Myxoma virus, a poxvirus that is known to be pathogenic only in rabbits, has not been reported to infect normal tissues in humans or mice. We observed that when recombinant virus was injected directly into the lateral ventricle of the mouse brain, virally encoded red fluorescent protein was expressed in ependymal and subventricular cells. Cells were positive for nestin, a marker of neural stem cells. Rapamycin increased the number of cells expressing the virally encoded protein. However, protein expression was transient. Cells expressing the virally encoded protein did not undergo apoptosis and the ependymal lining remained intact. Myxoma virus appears to be safe when injected into the brain despite the transient expression of virally derived protein in a small population of periventricular cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861319     DOI: 10.1099/vir.0.026690-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.

Authors:  Bingtao Tang; Zong Sheng Guo; David L Bartlett; David Z Yan; Claire P Schane; Diana L Thomas; Jia Liu; Grant McFadden; Joanna L Shisler; Edward J Roy
Journal:  Clin Cancer Res       Date:  2020-02-04       Impact factor: 12.531

2.  Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.

Authors:  Rosalinda A Doty; Jia Liu; Grant McFadden; Edward J Roy; Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2013-01

Review 3.  Oncolytic myxoma virus: the path to clinic.

Authors:  Winnie M Chan; Masmudur M Rahman; Grant McFadden
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

4.  A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro.

Authors:  Nahlah M Almansour; Elena Pirogova; Peter J Coloe; Irena Cosic; Taghrid S Istivan
Journal:  J Biomed Sci       Date:  2012-07-17       Impact factor: 8.410

5.  Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Authors:  Franz J Zemp; Brienne A McKenzie; Xueqing Lun; Lori Maxwell; Karlyne M Reilly; Grant McFadden; V Wee Yong; Peter A Forsyth
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

6.  A cautionary note on the selectivity of oncolytic poxviruses.

Authors:  Bingtao Tang; Zong Sheng Guo; David L Bartlett; Jia Liu; Grant McFadden; Joanna L Shisler; Edward J Roy
Journal:  Oncolytic Virother       Date:  2019-02-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.